Bio-Works Technologies AB (publ) (BIOWKS.ST)
SEK 1.36
(3.82%)
SEK 1.36
(3.82%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -39.38 Million SEK | 40.22% |
| 2022 | -65.87 Million SEK | 35.88% |
| 2021 | -102.74 Million SEK | -210.8% |
| 2020 | -33.05 Million SEK | 56.73% |
| 2019 | -76.4 Million SEK | -41.33% |
| 2018 | -54.06 Million SEK | 39.43% |
| 2017 | -89.24 Million SEK | -579.11% |
| 2016 | -13.14 Million SEK | -26.37% |
| 2015 | -10.4 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 FY | -39.38 Million SEK | 40.22% |
| 2023 Q1 | -42.97 Million SEK | 34.77% |
| 2023 Q2 | -42.97 Million SEK | 0.0% |
| 2023 Q4 | -39.38 Million SEK | 0.0% |
| 2023 Q3 | -39.38 Million SEK | 8.35% |
| 2022 Q3 | -65.87 Million SEK | 17.56% |
| 2022 Q1 | -79.9 Million SEK | 22.23% |
| 2022 Q2 | -79.9 Million SEK | 0.0% |
| 2022 FY | -65.87 Million SEK | 35.88% |
| 2022 Q4 | -65.87 Million SEK | 0.0% |
| 2021 FY | -102.74 Million SEK | -210.8% |
| 2021 Q1 | -43.15 Million SEK | -30.55% |
| 2021 Q4 | -102.74 Million SEK | 0.0% |
| 2021 Q3 | -102.74 Million SEK | -138.07% |
| 2021 Q2 | -43.15 Million SEK | 0.0% |
| 2020 Q4 | -33.05 Million SEK | 0.0% |
| 2020 Q2 | -54.3 Million SEK | 16.77% |
| 2020 Q3 | -33.05 Million SEK | 39.12% |
| 2020 Q1 | -65.24 Million SEK | 14.61% |
| 2020 FY | -33.05 Million SEK | 56.73% |
| 2019 Q4 | -76.4 Million SEK | 13.5% |
| 2019 Q2 | -35.61 Million SEK | 23.15% |
| 2019 FY | -76.4 Million SEK | -41.33% |
| 2019 Q1 | -46.35 Million SEK | 14.26% |
| 2019 Q3 | -88.32 Million SEK | -147.98% |
| 2018 Q4 | -54.06 Million SEK | 0.0% |
| 2018 Q1 | 89.24 Million SEK | 200.0% |
| 2018 FY | -54.06 Million SEK | 39.43% |
| 2018 Q2 | -71.24 Million SEK | -179.82% |
| 2017 Q4 | -89.24 Million SEK | -249.02% |
| 2017 FY | -89.24 Million SEK | -579.11% |
| 2017 Q1 | 13.14 Million SEK | 200.0% |
| 2017 Q3 | -25.57 Million SEK | 0.0% |
| 2016 FY | -13.14 Million SEK | -26.37% |
| 2016 Q4 | -13.14 Million SEK | 0.0% |
| 2015 FY | -10.4 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -2.16 Million SEK | -1722.397% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 88.196% |
| NextCell Pharma AB | -46.79 Million SEK | 15.834% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -34.03% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 123.713% |
| AcouSort AB (publ) | -23.98 Million SEK | -64.187% |
| OncoZenge AB (publ) | -12.62 Million SEK | -211.887% |
| Xintela AB (publ) | -7.8 Million SEK | -404.316% |
| Ziccum AB (publ) | -2.13 Million SEK | -1742.864% |
| Active Biotech AB (publ) | -33.2 Million SEK | -18.62% |
| Alzinova AB (publ) | -21.22 Million SEK | -85.537% |
| Amniotics AB (publ) | -5.63 Million SEK | -599.254% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 21.269% |
| BioArctic AB (publ) | -606.58 Million SEK | 93.508% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 829.296% |
| Camurus AB (publ) | -1.16 Billion SEK | 96.621% |
| Cantargia AB (publ) | -139.74 Million SEK | 71.819% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -4166.739% |
| CombiGene AB (publ) | -101.44 Million SEK | 61.177% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 52.023% |
| Genovis AB (publ.) | -43.94 Million SEK | 10.375% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 52.972% |
| Mendus AB (publ) | -96.29 Million SEK | 59.102% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 71.493% |
| Kancera AB (publ) | -45.69 Million SEK | 13.81% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 52.091% |
| LIDDS AB (publ) | -13.51 Million SEK | -191.459% |
| Lipum AB (publ) | -8.46 Million SEK | -365.233% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -23.35% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 173.994% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -106.621% |
| Saniona AB (publ) | 40.44 Million SEK | 197.367% |
| Simris Alg AB (publ) | 85.07 Million SEK | 146.291% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 69.588% |
| Intervacc AB (publ) | -88.16 Million SEK | 55.329% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 21.132% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 292.014% |
| Corline Biomedical AB | -17.01 Million SEK | -131.495% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 52.973% |
| Aptahem AB (publ) | 2.9 Million SEK | 1453.965% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 88.032% |
| Fluicell AB (publ) | -2.76 Million SEK | -1325.335% |
| Biovica International AB (publ) | -58.73 Million SEK | 32.952% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 12.904% |
| Abliva AB (publ) | -57.24 Million SEK | 31.198% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 79.773% |
| 2cureX AB (publ) | -13.4 Million SEK | -193.83% |
| I-Tech AB | -83.26 Million SEK | 52.701% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 129.235% |
| Cyxone AB (publ) | -16.67 Million SEK | -136.245% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 29.532% |
| Biosergen AB | -1.88 Million SEK | -1991.45% |
| Nanologica AB (publ) | -9.38 Million SEK | -319.493% |
| SynAct Pharma AB | -61.75 Million SEK | 36.232% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -83.899% |
| BioInvent International AB (publ) | -236.3 Million SEK | 83.334% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -197.69% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 41.151% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -660.135% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -89.4% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -1225.101% |